[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"circadian-rhythms\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:circadian-rhythms":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,41,76,102],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100538898","biomarkers-for-peripheral-circadian-clocks-in-humans-100538898",false,"NCT06296823","Biomarkers for Peripheral Circadian Clocks in Humans","Inclusion Criteria:\n\n1\\) 17-35 years old 2) English speaking 3) Healthy 5) Altitude history: Currently residing at Denver altitude or higher\n\nExclusion Criteria:\n\n1\\. Any medical, psychiatric, or sleep disorder.",true,"ALL","17 Years","35 Years",{"count":20,"type":21},14,"ESTIMATED","INTERVENTIONAL",[24],"NA","The purpose of this project is to improve our understanding of peripheral circadian rhythms in humans. Circadian clocks are present in most tissues of the body with importance for optimal physiological function, health, and behavior. This project will utilize simulated jetlag protocols to systematically test novel hypotheses about the regulation of peripheral circadian rhythms in humans. Specifically, we will examine how changes in the time of when we are exposed to light and the timing of when we eat impacts proteins in the blood and saliva that represent rhythms from clocks in the brain (e.g., rhythms of the hormones melatonin and cortisol coordinated by the brain) and rhythms from clocks in body tissues (e.g., proteins made by immune and bone cells, and cells in the stomach and liver). We also aim to discover new blood-based biomarkers of peripheral rhythms in humans. We anticipate our findings will be the first step in developing novel circadian based treatments for aligning peripheral clocks under conditions such as jetlag, and for developing novel circadian biomarkers that will advance our scientific understanding of circadian rhythms.",[27],"Circadian Rhythms","RECRUITING","2026-06-15",{"date":31,"type":32},"2026-06-17","ACTUAL",{"date":34,"type":32},"2023-09-01",{"date":36,"type":21},"2027-08-31",{"name":38,"class":39},"University of Colorado, Boulder","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":47,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":52,"conditions":53,"keywords":58,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":40},"100453468","sleep-and-circadian-mechanisms-in-hypertension-100453468","NCT05184933","Sleep and Circadian Mechanisms in Hypertension","Inclusion Criteria:\n\n* Ages 25-64\n* BMI 18.5-42kg\u002Fm2\n* Hypertension (average resting blood pressure between 130\u002F80 mmHg and 160\u002F100 mmHg)\n\nExclusion Criteria:\n\n* Over 5 pack-years of smoking;\n* Prior shift work within 12 months prior to the study;\n* Travel greater than three time zones for at least 3 months;\n* History of heart failure, cardiomyopathy, or history of bypass surgery, angioplasty, or previous myocardial infarction;\n* Acute or chronic diseases (except hypertension) that may affect outcome measures;\n* History of psychological conditions;\n* Sleep disorders, like severe sleep apnea, insomnia, etc.;\n* Prescription medications (Contraceptives and anti-hypertensive medications are permissible);\n* History of Illicit drug use and alcohol dependency;\n* 30 days free of cannabis use prior to the study;\n* Pregnancy;\n* Upper cut-off of 160\u002F100 mmHg for BP","25 Years","64 Years",{"count":50,"type":21},32,[24],"This study is a mechanistic clinical trial designed to investigate the effects of the circadian system and sleep on non-dipping blood pressure (BP) in people with hypertension (HTN).",[54,55,56,27,57],"Hypertension","Cardiovascular Diseases","Cardiovascular Risk Factors","Sleep",[59,60,61,62,63,64,65,66],"cardiovascular","circadian rhythms","sleep","blood pressure","constant routine","microneurography","hypertension","sleep regularization","2026-02-09",{"date":69,"type":32},"2026-02-11",{"date":71,"type":32},"2022-08-04",{"date":73,"type":21},"2029-03-30",{"name":75,"class":39},"Oregon Health and Science University",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":15,"sex":16,"minAge":82,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":86,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":40},"100617340","the-effect-of-a-continuous-1-hour-time-delay-on-circadian-rhythms-100617340","NCT07317349","The Effect of a Continuous 1-Hour Time Delay on Circadian Rhythms","Inclusion Criteria\n\n* Healthy adults aged 23-45 years\n* Part of a heterosexual, cohabiting couple willing to participate together in a five-day in-laboratory study\n* Both partners meet all inclusion criteria\n* Completion of at least upper-secondary education\n* Maintain a regular sleep-wake schedule\n* Habitual sleep timing within a normative range (non-extreme chronotype), assessed using the Morningness-Eveningness Questionnaire (MEQ) or the Munich Chronotype Questionnaire (MCTQ)\n* Both partners fall within the acceptable chronotype range to ensure aligned sleep-wake patterns\n* Low seasonality scores on the Seasonal Pattern Assessment Questionnaire (SPAQ)\n* Free from underlying sleep or mood disorders\n\nExclusion Criteria\n\n* Engages in night-shift work or maintains an irregular work or sleep schedule\n* International travel involving a time-zone change of more than two hours within the past two months, or anticipated travel before study completion\n* Diagnosed neurological, psychiatric, or sleep disorder (e.g., insomnia, sleep apnea, bipolar disorder)\n* High risk of sleep apnea, defined as a Berlin Questionnaire score \\>2 (Lauritzen et al., 2018)\n* Use of medications known to affect sleep, alertness, melatonin secretion, or circadian timing\n* Unable or unwilling to comply with behavioral restrictions, including refraining from electronic devices displaying time cues unless clocks are removed and devices are disconnected from Wi-Fi\n* Unable or unwilling to comply with consumption restrictions, including abstaining from caffeine, alcohol, and melatonin-rich foods during the study\n* Extreme chronotype, defined as a habitual midsleep time outside 03:00-05:00 on the MCTQ or classification as an extreme morning or extreme evening type on the MEQ\n* Daily caffeine consumption exceeding 400 mg (approximately 4-5 cups of coffee)\n* Current smoker or smoking within the past six months","23 Years","45 Years",{"count":85,"type":21},40,[24],"The purpose of this study is to investigate whether the experience of a daily time delay can affect our internal circadian rhythm.",[27,89,57],"Time Perception",[91,92],"circadian phase delay","Healthy adults","2026-01-14",{"date":95,"type":32},"2026-01-16",{"date":97,"type":21},"2025-12-20",{"date":99,"type":21},"2027-08-30",{"name":101,"class":39},"University of Aarhus",{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":15,"sex":16,"minAge":108,"maxAge":109,"enrollmentInfo":110,"targetDuration":4,"studyType":22,"phases":112,"briefSummary":113,"conditions":114,"keywords":117,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":40},"100580031","the-effect-of-light-intervention-on-recovery-in-individuals-with-opioid-use-disorder-oud-100580031","NCT06832007","The Effect of Light Intervention on Recovery in Individuals With Opioid Use Disorder (OUD)","Inclusion Criteria:\n\n* All Participants\n* Between 18 and 60 years old\n* Fluent in English\n* Able to provide written informed consent\n\nOUD\n\n* DSM-5 diagnosis of an OUD.\n* ≥12 months of lifetime opioid use\n* Positive on urine drug screen for buprenorphine or methadone\n* Receiving opioid agonist therapy for OUD (e.g., methadone or buprenorphine) with a stable dose for the past month. Must have been stabilized on OMT medication, since the increasing of doses during induction phase might interfere with outcomes and unstable patients might experience strong withdrawal symptoms in the morning which makes them unsuitable for a home-based BLT.\n* Other substance use was not exclusionary, but opioids were identified as primary.\n\nExclusion Criteria:\n\nAll Participants\n\n* Head trauma with loss of consciousness for more than 30 minutes as determined by medical history.\n* history of seizures\u002Fepilepsy.\n* Pregnant and\u002For currently breast-feeding.\n* Presence of ferromagnetic objects in the body that are contraindicated for MRI or fear of enclosed spaces.\n* Eye disease including disease of the anterior and posterior segment of the eye, cataracts, retinopathy, glaucoma, amblyopia, scotoma, color or night blindness, corneal pathologies, macular degeneration, or retinitis pigmentosa reported by history or identified by eye exam\n* History of eye surgery\n* Chronic migraine triggered by bright light\n* worked night shift or traveled across\\>2 time zones in the past month\n\nOUD\n\n* diagnosis of substance use disorder other than for opioids that was deemed to be primary\n* lifetime diagnosis of schizophrenia, bipolar disorder, or suicidality.\n* History of light treatment\n* Unstable dose of psychiatric medication (hypnotics, sleep aids, and antidepressants must be stable for 30 days before and during the study)\n\nHC\n\n* Current or past DSM-IV or DSM-5 diagnosis of a psychiatric disorder including substance use disorder (except for nicotine\u002Fcaffeine).\n* Current DSM-5 sleep-wake disorders including insomnia disorder","18 Years","60 Years",{"count":111,"type":21},105,[24],"Opioid use disorder (OUD) is a chronic relapsing disorder and is well-known for its high-risk rate of overdoses and death. In OUD, sleep and circadian disruptions are highly prevalent, interfere with opioid maintenance treatment outcomes and increase the risk of relapse. So far, commonly used pharmacological sleep treatments fail to improve sleep or decrease illicit drug use in OUD. Thus, there is an urgent need to fill this research gap.\n\nPrevious work showed that OUD patients who were receiving opioid agonist treatment (MOUD+) exhibited greater irregularity of sleep-wake cycle. In OUD patients, sleep-wake irregularity was associated with years of heroin use and low light exposure. Bright light therapy (BLT) is a very promising circadian\u002Fsleep intervention for several sleep, psychiatric and neurological disorders. BLT improved circadian, sleep outcomes and negative mood. In a pilot study, BLT improved objective and subjective sleep in patients with alcohol use disorder. Here investigators proposed an intervention study for MOUD+ patients to determine effects of BLT as an adjunct treatment on sleep and circadian outcomes including endogenous circadian rhythm, rest-activity rhythm and sleep neurophysiology (Primary objectives); and to determine effects of BLT on brain function and on clinical outcomes including negative affect, craving and illicit drug use and whether changes in sleep and circadian rhythm mediate the BLT effect on brain recovery and clinical outcomes (Secondary objectives).\n\nFifty MOUD+ will be assigned either to bright light or to dim light group for 2 weeks. The groups will be matched for age, sex, race and OUD medication (Methadone vs Buprenorphine). The study will run throughout the year such that it occurs during all seasons. Light exposure will be measured with light sensor for additional control. All MOUD+ participants will have a daily 30-min light exposure (bright or dim blue light) in the morning after their habitual wake-up time and will be asked to avoid evening light before bed. Dim light melatonin onset, accelerometer, sleep EEG and questionnaires will be used to measure objective and subjective sleep and circadian outcomes. For brain function, cue-reactivity task will be used to assess brain activation during drug craving. Resting state functional connectivity and brain state dynamics will be assessed by rsfMRI. Mood, opiate craving and illicit drug use will be assessed. All measures will be repeated before and after the treatment. Investigators expect that BLT would normalize sleep and circadian outcomes, attenuate impairments in brain functions and result in better clinical outcomes. If successful, light therapy will provide add-on benefits to opioid agonist therapy and facilitate OUD recovery process.",[115,57,27,116],"Opioid Use Disorder","fMRI Research",[118,61,60,119],"opioid use disorder","fMRI research","2025-10-16",{"date":122,"type":32},"2025-10-20",{"date":124,"type":32},"2025-09-06",{"date":126,"type":21},"2028-09-16",{"name":128,"class":39},"University of Alabama at Birmingham"]